Deucravacitinib, A New Oral Option for Patients with Moderate to Severe Psoriasis
Deucravacitinib provides an effective treatment for moderate to severe psoriasis patients and is long-term safe for four years.
Deucravacitinib provides an effective treatment for moderate to severe psoriasis patients and is long-term safe for four years.
